314 related articles for article (PubMed ID: 25913479)
1. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.
Schweitzer J; Zimmermann M; Rasche M; von Neuhoff C; Creutzig U; Dworzak M; Reinhardt D; Klusmann JH
Ann Hematol; 2015 Aug; 94(8):1327-36. PubMed ID: 25913479
[TBL] [Abstract][Full Text] [Related]
2. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial.
Teyssier AC; Lapillonne H; Pasquet M; Ballerini P; Baruchel A; Ducassou S; Fenneteau O; Petit A; Cuccuini W; Ragu C; Preudhomme C; Mercher T; Sirvent N; Leverger G
Pediatr Hematol Oncol; 2017 Nov; 34(8):425-427. PubMed ID: 29303660
[TBL] [Abstract][Full Text] [Related]
3. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.
Inaba H; Zhou Y; Abla O; Adachi S; Auvrignon A; Beverloo HB; de Bont E; Chang TT; Creutzig U; Dworzak M; Elitzur S; Fynn A; Forestier E; Hasle H; Liang DC; Lee V; Locatelli F; Masetti R; De Moerloose B; Reinhardt D; Rodriguez L; Van Roy N; Shen S; Taga T; Tomizawa D; Yeoh AE; Zimmermann M; Raimondi SC
Blood; 2015 Sep; 126(13):1575-84. PubMed ID: 26215111
[TBL] [Abstract][Full Text] [Related]
5. Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome: A Retrospective Study in China.
Wang Y; Lu A; Jia Y; Zuo Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e301-e308. PubMed ID: 33257285
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome.
Hara Y; Shiba N; Ohki K; Tabuchi K; Yamato G; Park MJ; Tomizawa D; Kinoshita A; Shimada A; Arakawa H; Saito AM; Kiyokawa N; Tawa A; Horibe K; Taga T; Adachi S; Taki T; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):394-404. PubMed ID: 28063190
[TBL] [Abstract][Full Text] [Related]
7. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.
Klusmann JH; Reinhardt D; Zimmermann M; Kremens B; Vormoor J; Dworzak M; Creutzig U; Klingebiel T
Haematologica; 2012 Jan; 97(1):21-9. PubMed ID: 21933851
[TBL] [Abstract][Full Text] [Related]
8. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.
Sander A; Zimmermann M; Dworzak M; Fleischhack G; von Neuhoff C; Reinhardt D; Kaspers GJ; Creutzig U
Leukemia; 2010 Aug; 24(8):1422-8. PubMed ID: 20535146
[TBL] [Abstract][Full Text] [Related]
9. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
10. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
11. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
12. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience.
Athale UH; Razzouk BI; Raimondi SC; Tong X; Behm FG; Head DR; Srivastava DK; Rubnitz JE; Bowman L; Pui CH; Ribeiro RC
Blood; 2001 Jun; 97(12):3727-32. PubMed ID: 11389009
[TBL] [Abstract][Full Text] [Related]
13. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
15. Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients.
Zhang W; Dun J; Li H; Liu J; Chen H; Yu H; Xu J; Zhou F; Qiu Y; Hao J; Hu Q; Wu X
Hematology; 2023 Dec; 28(1):2231731. PubMed ID: 37522469
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and prognosis of pediatric acute megakaryocytic leukemia].
Luo TM; Yu J; An XZ
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Jun; 23(6):613-620. PubMed ID: 34130784
[TBL] [Abstract][Full Text] [Related]
18. Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children.
Paredes-Aguilera R; Romero-Guzman L; Lopez-Santiago N; Trejo RA
Am J Hematol; 2003 Jun; 73(2):71-80. PubMed ID: 12749007
[TBL] [Abstract][Full Text] [Related]
19. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
[TBL] [Abstract][Full Text] [Related]
20. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.
de Rooij JD; Hollink IH; Arentsen-Peters ST; van Galen JF; Berna Beverloo H; Baruchel A; Trka J; Reinhardt D; Sonneveld E; Zimmermann M; Alonzo TA; Pieters R; Meshinchi S; van den Heuvel-Eibrink MM; Zwaan CM
Leukemia; 2013 Dec; 27(12):2280-8. PubMed ID: 23531517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
